Home>
Stocks>
Medicamen Biotech Ltd

Medicamen Biotech Ltd (MEDICAMEQ)

₹519.5▲0.43%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Medicamen Biotech Ltd share Performance

₹512.8
₹530
₹519.5
1.29%
Low
Day's Volatility:3.31%
High
2.02%
₹355.45
₹845
₹519.5
31.58%
Low
52 Weeks Volatility:94.23%
High
62.66%

Returns %
1 Month Return	18.68 %
3 Month Return	-0.47 %
1 Year Return	-25.02 %

Market Stats
Previous Close	₹517.25
Open	₹525.80
Volume	8,818.00
Upper Circuit	-
Lower Circuit	-
Market Cap	₹654.38Cr

Company Information

Medicamen Biotech Ltd. is a globally recognized public limited company involved in the manufacturing and selling of pharmaceutical products in overseas and domestic markets. It has two ultra modern manufacturing facilities in Bhiwadi (Rajasthan) and Haridwar (Uttarakhand) equipped with the latest state of the art technology, manned by qualified personnel and hardworking workforce. In 2005, the second unit was installed in the tax-free zone in Haridwar with a facility to produce Non Betalactum tablets, capsules, oral liquids, and ointments. In 2009, the company added analgesic, antibiotics and Antifilarial/TB drugs and started supplying bulk Anti-bacterial products like Cotrimoxazole to foreign partners. The company has been recognized for its commitment to provide quality medicines at competitive prices whilst also being socially responsible. In 2015, Shivalik Rasayan acquired 44.15% of the paid-up equity share capital of the Company. The company acquired 100% stake of OPAL Pharmaceuticals in 2019-20 and merged with the same. In January 2022, 12 Oncology products were launched in the domestic market. Overall, the company has been focusing on delivering quality products to overseas and domestic customers since 1993 through cost-effective manufacturing and distribution.

Share Price: ₹519.50 per share as on 08 May, 2024 04:01 PM
Market Capitalisation: ₹654.38Cr as of today
Revenue: ₹46.50Cr as on December 2023 (Q4 23)
Net Profit: ₹2.03Cr as on December 2023 (Q4 23)
Listing date: 27 Oct, 2021
Chairperson Name: Rahul Bishnoi

Organisation	Medicamen Biotech Ltd
Headquarters
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Medicamen Biotech Ltd

Medicamen Biotech Shares Jump 20% on US FDA Inspection - 29 Apr, 2024
Shares of Medicamen Biotech jumped 20% to hit the upper circuit after the United States Food and Drug Administration inspected its oncology formulation facility in Haridwar. The inspection closed with six procedural observations, which were complied with proactively and acknowledged by the auditor. However, the final approval (EIR) is expected after submission of formal response to FDA.
Insiders of Medicamen Biotech Sell Shares - 27 Apr, 2024
Insiders of Medicamen Biotech have sold ₹20m worth of stock over the last year at an average price of ₹170, which is higher than the current price. Geetika Madan made the biggest insider sale in the last 12 months, selling ₹11m worth of shares at a price of ₹384 each.

Fundamentals of Medicamen Biotech Ltd

Insights on Medicamen Biotech Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.51 Cr → 2.03 Cr (in ₹), with an average increase of 25.6% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 8 quarters, 23.09 Cr → 47.33 Cr (in ₹), with an average increase of 9.1% per quarter
NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 57.6% return, outperforming this stock by 82.6%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 43.21% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
Price Dip
In the last 7 days, MEDICAMEQ stock has moved down by -7.4%
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 0.21% to 0.11% in Mar 2024 quarter
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 55.90% to 55.69% in Mar 2024 quarter